Thermo Fisher Scientific's $13.6 Billion Acquisition of Life Technologies Boosts Flagging M&A Numbers May 01, 2013 | Press Release
Burrill Securities Launches Institutional Breakthrough Series April 29, 2013 | Press Release
Big Biotech Outpaces Big Pharma, Burrill & Company says April 16, 2013 | Press ReleaseSee all News
Chen Yee LiawAssociate
Chen Yee joined Burrill & Company in 2011, and has been working with the Malaysian Life Sciences Capital Fund (MLSCF) since 2009. She is instrumental in evaluating biotechnology companies in the cleantech sector, where she helps develop insights and investment strategy for the Malaysian fund through market, technical, competitive and financial analyses. Chen Yee also previously served as Business Analyst at Abunda Nutrition, a portfolio company of MLSCF, which later got acquired by Evolva SA. At Abunda/Evolva, she was actively involved in business and corporate development activities, where she helped identify potential molecules for pipeline expansion, developed insights to guide manufacturing and commercialization strategies, as well as performed financial modeling. Prior to Burrill and MLSCF, Chen Yee was a Summer Business Analyst at Deloitte Consulting, in Strategy & Operations. She also did research at Caltech, elucidating the molecular basis of early T-cell development defects that may impact autoimmunity in a Type 1 diabetes mouse model. She holds a B.S. (Honors) in Biology and Business Economics from the California Institute of Technology (Caltech), and was recipient of the prestigious Upper Class Merit Award.